|Bid||46.88 x 1200|
|Ask||46.89 x 1300|
|Day's Range||46.84 - 46.92|
|52 Week Range||42.63 - 57.82|
|Beta (5Y Monthly)||0.46|
|PE Ratio (TTM)||11.84|
|Forward Dividend & Yield||1.90 (4.04%)|
|Ex-Dividend Date||May 30, 2023|
|1y Target Est||62.50|
Subscribe to Yahoo Finance Plus to view Fair Value for SNY
Senior Biden administration officials met with the makers of RSV immunizations for children this week to underscore the need for manufacturers such as Sanofi and AstraZeneca to urgently meet demand as winter approaches, the White House said on Tuesday. At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the immunizations targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults.
Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.
Hudson sought to emulate the efficiency of a race car team that recently set the world record for quickest pit stop.